Maximum quantity allowed is 999
请选择数量
CAS RN: 366017-09-6 | 产品编码: M3058
Mubritinib
×
![]()
×
| 产品编码 | M3058 |
| 纯度/分析方法 | >98.0%(HPLC) |
| 分子式/分子量 | C__2__5H__2__3F__3N__4O__2 = 468.48 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷藏 (0-10°C) |
| 应避免的情况 | 加热 |
| 包装和容器 | 25MG-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 366017-09-6 |
| Reaxys-RN | 13498857 |
| PubChem物质ID | 354335238 |
| MDL编号 | MFCD09954135 |
技术规格
| Appearance | White to Gray to Brown powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 158.0 to 162.0 °C |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 160 °C |
GHS
相关法规
运输信息
| HS编码* | 2934.99-000 |
应用
ヒト上皮成長因子受容体2 (HER2) チロシンキナーゼ阻害剤，ムブリチニブ
Small-molecule protein kinase inhibitors are widely used to elucidate cellular signaling pathways. Mubritinib (TAK 165) is a selective inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Reportedly, mubritinib specifically inhibits HER2 tyrosine kinase IC50 6 nmol/L and do not inhibit other types of tyrosine kinase up to 25,000 nmol/L.1) Several reports suggest HER2 expression in bladder cancer, renal cell carcinoma (RCC) and androgen-independent prostate cancer. However, the clinical development program for mubritinib as an anti-cancer drug was discontinued. (The product is for research purpose only.)
References
- 1)Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo
- 2)Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
参考文献
文章/手册
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。